This study was to evaluate effects of Sativex on electrocardiogram (ECG) traces when
administered at its therapeutic dose of 8 sprays per day and at multiples of the therapeutic
dose (24 or 36 sprays per day), and to evaluate its safety and tolerability.
Phase:
Phase 1
Details
Lead Sponsor:
GW Pharmaceuticals Ltd.
Treatments:
Fluoroquinolones Moxifloxacin Nabiximols Norgestimate, ethinyl estradiol drug combination